Clinical Trial

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Study acronym: CHERRY-PICK
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to identify HER2-positive early-stage breast cancer patients who could benefit from neoadjuvant treatment using PHESGO™ (pertuzumab and trastuzumab) without chemotherapy. The approach involves utilizing specific biomarkers (HR and HER2 IHC status) to select participants whose tumors strongly rely on the HER2 pathway, potentially benefiting from a HER2-targeted approach without chemotherapy concurrently.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-10-03; most recent amendment 2026-02-11.
Status change: Recruiting → Active, Not Recruiting 2026-02-11
Status change: Not Yet Recruiting → Recruiting 2025-02-03
Trial Details
NCT Number NCT06068985
Lead Sponsor Latin American Cooperative Oncology Group
Collaborators: Roche Pharma AG, Oncoclínicas
Conditions Breast Cancer, HER2-positive Breast Cancer
Enrollment 63 participants
Start Date 2024-09-05
Primary Completion 2026-04 (estimated)
Study Completion 2032-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-12